Skip to main content
Premium Trial:

Request an Annual Quote

Metrion Biosciences Closes £2.7M in Equity Financing

NEW YORK – Drug discovery firm Metrion Biosciences said Tuesday that it has closed on £2.7 million ($3.7 million) in new equity financing, including £2.25 million from lead investor Gresham House Ventures.

Cambridge, UK-based Metrion said it will use the funding to expand its laboratories, invest in specialty equipment, develop its cell line library, add GLP cardiac safety services, and expand its business to the US.

The firm specializes in ion channel contract research and drug discovery, and offers a panel of in vitro cardiac ion channel safety assays; translational native cell and phenotypic assays for neurological and cardiotoxicity testing; and a range of other ion channel screening services.

"This new investment, led by Gresham House Ventures, is a key part of Metrion's strategic development, enabling the company to expand its laboratories in Cambridge, UK, provide enhanced services to customers, and invest more extensively in US business development," Keith McCullagh, chairman of Metrion Biosciences, said in a statement.

In connection with the financing, Maya Ward, associate director at Gresham House Ventures, has been appointed to Metrion's board of directors.

The Scan

Transplant Tests Edited Pig Kidneys

The Associated Press reports a University of Alabama-Birmingham team transplanted genetically modified pig kidneys into a brain-dead human patient.

UK Changes Some Gene-Edited Crop Rules

A new law may enable gene-edited crops to be sold in the UK within about five years, New Scientist says.

Pill Works Against Omicron in Lab

Pfizer's antiviral pill to treat SARS-CoV-2 appears to work against the Omicron variant, the Wall Street Journal reports.

Nature Papers Find Genetic Risk Factor for Smell, Taste Loss in COVID-19; Analyze TB Granulomas

In Nature this week: genome-wide association study find locus linked to the risk COVID-19 patients losing their sense of taste or smell, and more.